奥沙利铂联合替吉奥胶囊治疗晚期胃癌的临床观察

Clinical Study of Oxaliplatin Combined with S1 Capsule in the Treatment of Patients with Advanced Gastric Cancer

目的观察奥沙利铂联合替吉奥(S1)胶囊方案治疗晚期胃癌的临床疗效及不良反应。方法 56例晚期胃癌患者,采用以下方案化疗:吉奥胶囊每天80mg/m2,分2次,餐后口服,d1～d14;奥沙利铂130mg/m2,静脉滴注3h,d1;28天为1个周期,至少完成2个周期。按RECIST1.1标准评价客观疗效和不良反应。结果 56例患者均可以评价疗效。CR4例(7.1%),PR23例(41.1%),SD17例(30.4%),PD12例(21.4%),RR48.2%,DCR78.6%。中位疾病进展时间(TTP)为9.3个月,中位生存期(MST)为11.2个月。不良反应主要是骨髓抑制,胃肠道反应及外周神经毒性。结论奥沙利铂联合替吉奥方案治疗晚期胃癌的近期疗效较好,不良反应可以耐受,值得进一步研究应用。

Objective To evaluate the efficacy and toxicity of oxaliplatin combined with S1 capsule in the treatment of advanced gastric cancer patients.Methods A total of 56 patients with advanced gastric cancer were treated with chemotherapy of intravenous：oxaliplatin 130 mg/m2 in day 1 and S1 capsule 80 mg/m2 twice daily for 14 days.The chemotherapy was repeated every 28 days.All patients received 2 cycles at least.Efficacy and toxicities were evaluated according to the RECIST 1.1 standard.Results Of the 56 patients,there were 4（7.1%）complete remission（CR）,23（41.1%）partial remission（PR）,17（30.4%）stable disease（SD）,and 12（21.4%）progression disease（PD）.The total response rate was 48.2%.The disease control rate（DCR）was 78.6%.The median time to progression（mTTP）was 9.3 months.The median survival time（MST）was 11.2 months.The major toxicities included leucopenia,nausea,vomiting and neurosensory abnormity.Conclusion Oxaliplatin combined with S1 capsule is effective and tolerable in the treatment of patients with advanced gastric cancer.